News Image

Kaleido Biosciences to Appoint Dr. Alison Long as Chief Medical Officer

Provided By Globe Newswire

Last update: Nov 10, 2021

LEXINGTON, Mass., Nov. 10, 2021 (GLOBE NEWSWIRE) -- Kaleido Biosciences, Inc. (Nasdaq: KLDO), a clinical-stage biotech company with a differentiated, small-molecule approach to treating inflammatory conditions and diseases by selectively targeting the resident microbiome to restore gut-immune homeostasis, today announced the appointment of Alison Long, M.B.B.Ch., Ph.D., to its leadership team as Chief Medical Officer, effective December 15, 2021. In her new role, Dr. Long will be responsible for leading the development of Kaleido’s ongoing and future clinical programs, including the development of KB295 and KB109 in ulcerative colitis and chronic obstructive pulmonary disease, respectively.

Read more at globenewswire.com
Follow ChartMill for more